FABHALTA (iptacopan), FDA Approved for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria, Available at Biologics by McKesson
Biologics by McKesson was selected as a specialty pharmacy provider for FABHALTA, the first oral monotherapy approved for adults with paroxysmal nocturnal hemoglobinuria.